Member Info for LlamaFarmer

Nasdaq listing anyone?

Dennis Purcell presenting.

Anthony Tennyson did mention it in his recent interview!

LUCID Capital Markets

Our sector specialists deliver differentiated demand and broad institutional coverage, supported by long-standing relationships with corporate clients and the buy-side community. As one of the largest firms on the NYSE in terms of membership, footprint, and execution volume, our high-touch trading desk is dedicated to providing exceptional support and executions for our clients. Our traders utilize top-tier algorithmic trading tools to access diverse sources of liquidity, enabling clients to execute their strategies and achieve their objectives across both listed and NASDAQ issues

At Lucid Capital Markets, our focus is on connecting clients with the right investors, ensuring that every match is made with precision and purpose. We understand that success in capital markets isn't about sheer volume but about the quality of connections and the strategic alignment between investors and opportunities. Our approach prioritizes meaningful engagements and targeted investor relationships that drive optimal outcomes for our clients.

Anthony said that due to the experience of Dennis Purcell he is the man to talk to the Pharmas at the appropriate time.

Here we go ....

Anthony explained the copyright over their 120 page therapy manual.

Copyright lasts longer than any patent or the 8+2 years for the NHS.

Uk copyright 70 years.

Usa copyright 95 years from date of corporate publication.

"Any one causing us too many problems will be legally pursued"

That adds a lot of value, as that length of time can cover multiple license periods

Re 10m buy

It would explain why the price was held to collect it in and that the 3m uncrossing trade then nudged back to 36p as it had been filled?

That SVNS are in discussions with SIX Pharmas about licensing SVN001 is VERY interesting news, Anthony stated this will be done this year (in 2025)

Additional info he provided was that SVN 001 and SVN002 are both being developed in line wih licensing requirements for both the UK/EU and the USA.

002 is utilising Spravatos data and the FCA have allowed this to fastrack it.

Dennis Purcell is presenting on Thursday in the USA with two other top people.

Imagine the USA can look over it at the weekend.

I'm looking more at next week for the S.P. to really take off, as others have said, add if it dips or just pay the money and get what you want.

Personally with the investors stumping up a 125% increase over their previous raise I can't see a dip.

Opens at 0.35 and moves to 0.50?

Licensing SVN 001 is £60m plus bonus payments thats up to circa 1.6p on its own?

Anthony said svns in talks with multiple pharmas over licensing SVN001.

SVN002 Dennis Purcell is the man to talk to USA pharma when the time is right.

Then 014 ptsd will be devrloped.

Then depression and Drugs.

Once SVN001 is licensed that gives circa £60m plus further licensing oayments i.e. fully self funded for all products.

You will want to make time (45 mins ) to listen to this.

Anthony Tennyson

Svn001 in multiple talks.

Svn 002 if your listeners like the sales curve on Spravato ($1.3b and climbing) then theyll like what we have planned for SVN002, many U.S. multinationals not just J & J, lots of deals over $5B for mental health pharma.

https://audioboom.com/posts/8747765-sunday-roast-season-finale-svns-mast-atn-prem-wsbn-miri-afp-matd-pow-bzt-est-g

Josh Obsidian.... if you want to try and talk down to investors, the details matter, keep up at the back.

Its 24 hours and that doesnt have to be any trading days if its a weekend .. you checked your emails?

Lemming Investor Research Newsletter.

We declare all financial interests in any Company we feature. We also inform our subscribers of our intention to sell at least 24 hours before we do.

Vs

As for Lemming Investor — they always declare a financial interest and, crucially, give their members 48 hours' notice (that’s two full trading days, in case you’re struggling) before selling. They’re not tipsters, and therefore under no obligation to declare anything, but they choose to do so out of transparency. That, at the very least, should earn a modicum of respect.

Youve got to provide 24 hours notice to sell before you can flip into SVNS.

P.s.

Mike, Alex, and Elric are financially interested in SkinBioTherapeutics and OptiBiotix Health.

Mike, Alex, and Elric are financially interested in SkinBioTherapeutics and OptiBiotix Health.

They also promise to give 24 hours to subscribers before they sell.

No wonder they are "reaching out' to Karl Keegan .....

This game is poison at times, skin bio has already multibagged from 9p to 77p ... SVNS is the bright new stock.

They also promise to give 24 hours to subscribers before they sell.

No wonder they are "reaching out' to Karl Keegan .....

This game is poison at times, skin bio has already multibagged from 9p to 77p ... SVNS is the bright new stock, all that article does is reinforce that one is a sell ( with 24 hours notice ) and the other is a roaring buy!

Obsisian with the 17th July 2025 ac spamming multiple stocks.

Looked them up to see what I had missed as that article didn't make any sense.

They like a company called Skin Bio as one of their stock picks, Karl Keegan the Singer analyst is writing an article on Skin Bio and they state they hope it isnt published.

Our recent history (2019-2022

We do not claim to get it right 100% of the time. Still, when we do, our research has resulted in unearthing plenty of multi-baggers, such as ..... SkinBioTherapeutics (9p hi.

Adding further intrigue is the identity of the covering analyst: none other than Karl Keegan (Second part of this article), known to some as either the wizard—or witch—behind the much-speculated initiation note on SkinBioTherapeutics. One can only hope that particular piece remains on hold until we have the benefit of Croda’s numbers being released and absorbed by the market—followed, we assume, by the note itself. But I digress.

Reread that smear piece on Solvonis and it reads like, well like a smear piece really?

They also don't like any stocks that aren't discussed via their choice of a two tier subscription as they are holier than thou.

Bonesgt,

One of my investing principles.

If you can't explain an investment to someone in two minutes, clearly and succinctly in laymans terms then not many are going to invest so don't get involved.

Svn001 - Targeting UK & Europe

Stage:Phase 3.

Main competitors via the NHS disulfiram, naltrexone and acamprosate all with large side effects ranging from loose bowel to suicidal thoughts.

SVN002 - Targeting/ Licensed for USA,Japan, China

Stage:Phase 2b

Main Competitor - Spravato $1.3B p.a sales and growing fast!

Side effects - similar to SVN002 as both Esketaime but treatments scheduled for years vs 4 months for 002.

SVN014 PTSD treatment

Stage:Preclinical

Competition - limited

SVN Depression

Competition Limited

SVN Drug addiction

Competition - Limited.

So you can see that these investors are paying a premium on this latest raise to effectively bet on the results of a one horse race.

FDA Pathway 505b2 and the C.N.S. Library, focusing on depression and drug addiction.

So SVN002 and the FDA accelerated pathway using Spravatas data is one positive and reason to invest, svn 001 NHS is another.

Now link this existing 505b2 scheme that the Co has working knowledge of and link it with the C.N.S library having fully working patents until 2043 over all of its own data.

Then look at the latest raise at 0.30p and the Company moving straight into the large unmet needs of Depression and drug addiction!

Johnson and Johnson will be looking at SVN 002 and Spravata, svn002 is purposefully tailor made to have a competitive edge over Spravata and,also tailor made to fit the parameters of The 505b2 accelerated scheme.

Their competitors will also be looking over.

This new raise thrusts the companies pipeline into the medical arena, it will be noticed.

Unusual if they allow a disruptor with working patents, repurposing existing and safe medicines across so many unmet needs, without trying to take it out!

When is it used?

Modifications to existing drugs:

The 505(b)(2) pathway is commonly used when a company wants to develop a new formulation, dosage, or delivery method of an existing drug.

New combinations of approved drugs:

Combining two or more approved drugs into a single product can also be done through this pathway.

Solvonis Therapeutics, a biopharmaceutical company focused on mental health and substance use disorders, recently received positive feedback from the FDA regarding their lead asset, AWKN-002. This positive feedback, particularly the support for a 505(b)(2) pathway and progression to Phase 2b, has boosted investor confidence and led to a surge in Solvonis's share price. Solvonis is also in the process of acquiring Awakn Life Sciences, which is developing AWKN-002, further solidifying Solvonis's position in the mental health and addiction treatment space.

Here's a more detailed breakdown:

AWKN-002 and the FDA:

The FDA's positive feedback on AWKN-002, an oral thin film of esketamine combined with alcohol education, is a significant milestone for both Awakn and Solvonis. The agency's support for the 505(b)(2) pathway allows for a streamlined development process by leveraging existing data from other esketamine products, potentially accelerating market access.

Tricky, how many you up to now?

DVH the 1.6p a share offer ..